Zealand Pharma was founded in 1997 by five leading Danish scientists and was listed as a public company in 2015 on Nasdaq Copenhagen. It has since established a successful track record as a commercial-stage biotech company with a strategic focus on peptide drug serving high-value unmet patient needs in metabolic and gastrointestinal diseases.
